Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

625 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide and its role in the management of multiple myeloma.
Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A. Falco P, et al. Among authors: musto p. Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865. Expert Rev Anticancer Ther. 2008. PMID: 18533796 Review.
Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, Pozzi S, Sacchi S, Boccadoro M, Palumbo A; Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi. Musto P, et al. Expert Rev Anticancer Ther. 2008 Oct;8(10):1569-80. doi: 10.1586/14737140.8.10.1569. Expert Rev Anticancer Ther. 2008. PMID: 18925849 Review.
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.
Musto P, D'Auria F, Pietrantuono G, Baldini L, Bringhen S, Caravita T, Di Raimondo F, Morabito F, Offidani M, Petrucci MT, Tosi P, Gay F, Cavo M, Boccadoro M, Palumbo A. Musto P, et al. Curr Drug Targets. 2009 Oct;10(10):906-22. doi: 10.2174/138945009789577936. Curr Drug Targets. 2009. PMID: 19663768 Review.
Amyloid in bone marrow smears of patients affected by multiple myeloma.
Petruzziello F, Zeppa P, Catalano L, Cozzolino I, Gargiulo G, Musto P, D'Auria F, Liso V, Rizzi R, Caruso N, Califano C, Piro E, Musso M, Bonanno V, Pia Falcone A, Tafuto S, Di Raimondo F, De Laurentiis M, Pane F, Palombini L, Rotoli B. Petruzziello F, et al. Among authors: musto p. Ann Hematol. 2010 May;89(5):469-74. doi: 10.1007/s00277-009-0857-9. Epub 2009 Nov 6. Ann Hematol. 2010. PMID: 19894050
Primary plasma cell leukemia in the era of new drugs: has something changed?
Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P, Bringhen S, Offidani M, Omede' P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M, Palumbo A. Musto P, et al. Crit Rev Oncol Hematol. 2012 May;82(2):141-9. doi: 10.1016/j.critrevonc.2011.04.005. Epub 2011 Jun 29. Crit Rev Oncol Hematol. 2012. PMID: 21719304
Autoimmune cytopenias in chronic lymphocytic leukemia.
D'Arena G, Guariglia R, La Rocca F, Trino S, Condelli V, De Martino L, De Feo V, Musto P. D'Arena G, et al. Among authors: musto p. Clin Dev Immunol. 2013;2013:730131. doi: 10.1155/2013/730131. Epub 2013 Apr 16. Clin Dev Immunol. 2013. PMID: 23690826 Free PMC article. Review.
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M. Morabito F, et al. Among authors: musto p. Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5. Am J Hematol. 2014. PMID: 24273190 Free article.
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. Palumbo A, et al. Among authors: musto p. J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21. J Clin Oncol. 2014. PMID: 24449241 Clinical Trial.
625 results